期刊
FUTURE ONCOLOGY
卷 18, 期 7, 页码 771-779出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2021-1027
关键词
angiogenesis; atezolizumab; bevacizumab; immunotherapy; PD-L1; SCLC; VEGF
类别
资金
- Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) from ROCHE
- Astra-Zeneca
- Boehringer Ingelheim
Extended-stage small-cell lung cancer (ES-SCLC) is an aggressive subtype with poor prognosis. The combination of chemotherapy, antiangiogenic therapy, and immunotherapy may improve survival. The CeLEBrATE trial aims to assess the efficacy and safety of this combination treatment.
Lay abstract Extended-stage small-cell lung cancer (ES-SCLC) is a highly aggressive lung cancer subtype, accounting for 13-15% of all lung cancers. For several years, the standard treatment for this disease was based on polychemotherapy, with a rapid disease response but with an equally rapid disease progression. The new standard treatment has recently been changed, based on the results of two large clinical trials, which showed the efficacy and safety of the combination of chemotherapy with immunotherapy compared to chemotherapy alone. Nevertheless, prognosis of ES-SCLC remains poor, and new treatment strategies are urgently needed. Therefore, we designed the CeLEBrATE trial to investigate whether the combination of chemotherapy with antiangiogenetic therapy and immunotherapy is safe and could improve survival in patients with ES-SCLC. Based on improved survival from the addition of PD-L1 inhibitors in phase III trials, the combination of immunotherapy and platinum-doublet chemotherapy has become the new standard treatment for extended-stage small-cell lung cancer (ES-SCLC). Furthermore, the antiangiogenetic agent bevacizumab showed a longer progression-free survival by targeting VEGF that has pleiotropic effects, including immunosuppressive ones. We, therefore, hypothesized that targeting angiogenesis would improve the efficacy of chemoimmunotherapy. The CeLEBrATE trial is an open-label, multicenter, phase II study designed to assess the efficacy and safety of the combination of carboplatin and etoposide plus bevacizumab and atezolizumab in treatment-naive patients with ES-SCLC. The primary end point is overall survival rate at 1 year, while secondary end points include overall response rate, progression-free survival and toxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据